51264-68-7

Basic information

• Product Name: ETHYL 3-FORMYLPHENOXYACETATE
• Synonyms: ASISCHEM D29274;ETHYL 3-FORMYLPHENOXYACETATE;ETHYL 3-FORMYLPHENOXYACETATE(WXG01937)
• CAS NO: 51264-68-7
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21
• EINECS: -0
• Mol File: 51264-68-7.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 148-150°C 2mm
• Flash Point: 148-150°C/2mm
• Appearance: /
• Density: 1.169g/cm³
• Vapor Pressure: 0.000298mmHg at 25°C
• Refractive Index: 1.5320
• Sensitive: Air Sensitive
• BRN: 2109732
• CAS DataBase Reference: ETHYL 3-FORMYLPHENOXYACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-FORMYLPHENOXYACETATE(51264-68-7)
• EPA Substance Registry System: ETHYL 3-FORMYLPHENOXYACETATE(51264-68-7)

Safety Data

• Statements: 36/38
• Safety Statements: 26-36
• Hazardous Substances Data: 51264-68-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H12O4/c1-2-14-11(13)8-15-10-5-3-4-9(6-10)7-12/h3-7H,2,8H2,1H3

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 
• 64-17-5 ethanol 
• 37748-09-7 2-(3-formylphenoxy)acetic acid 

Downstream Products

• 1035095-40-9 ethyl 2-(3-((3-(1H-indazol-5-ylamino)piperidin-1-yl)methyl)phenoxy)acetate 
• 1202566-04-8 (S)-ethyl 2-(3-((3-(1H-indazol-5-ylamino)piperidin-1-yl)methyl)phenoxy)acetate 
• 1356862-44-6 N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]-1-{2-[3-(2-hydroxyethoxy)phenyl]ethyl}piperidine-4-carboxamide 
• 1356862-39-9 ethyl {3-[2-(4-{[(1R)-1-(4-fluorophenyl)-2-methylpropyl]carbamoyl}piperidin-1-yl)ethyl]phenoxy}acetate 
• 1356862-43-5 N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]-1-{2-[3-(2-hydroxyethoxy)phenyl]ethyl}piperidine-4-carboxamide hydrochloride 
• 1356862-16-2 ethyl [3-(2-oxoethyl)phenoxy]acetate 
• 1337935-24-6 C₁₄H₁₆O₄ 
• 1337935-36-0 C₁₄H₁₆O₄ 
• 1310698-03-3 ethyl 2-(3-((2-(piperidin-1-yl)ethylamino)methyl)phenoxy)acetate 
• 1228758-43-7 C₁₇H₂₄O₄Si 
• 1222376-71-7 (Z)-ethyl 2-(3-((7-(2-methoxyphenyl)-9-oxo-5H-benzo[h]thiazolo[2,3-b]quinazolin-10(6H,7H,9H)-ylidene)methyl)phenoxy)acetate 
• 1108147-84-7 ethyl (3-{1-[1-(1-methylcyclooctyl)piperidin-4-yl]-1H-benzimidazol-2-yl}phenoxy)acetate 
• 1089723-49-8 ethyl 2-(3-((4-(trimethylsilyl)benzylamino)methyl)phenoxy)acetate 
• 934826-25-2 (E)-2-(3-(3-(4-hydroxy-3-methylphenyl)-3-oxoprop-1-enyl)phenoxy)acetic acid 

Relevant articles and documents

Comparison between porphin, chlorin and bacteriochlorin derivatives for photodynamic therapy: Synthesis, photophysical properties, and biological activity

The development of novel photosensitizers is a challenging task for photodynamic therapy (PDT). Twelve novel photosensitizers (PSs), including porphins (P1-4), chlorins (C1-4) and bacteriochlorins (B1-4) were synthesized. The bacteriochlorins exhibited the longest absorption wavelength (λmax = 736 nm), which is higher than that of porphins (λmax = 630 nm) and chlorins (λmax = 644 nm). In vitro photodynamic activities on Eca-109 human esophageal carcinoma cells were evaluated by standard assays and all PSs showed photodynamic activity. Among them, B2 displayed the highest phototoxicity and the lowest dark toxicity. In addition, B2 exhibited best photodynamic antitumor efficacy on BALB/c nude mice bearing Eca-109 cells tumor. Therefore, B2 is a powerful and promising antitumor photosensitizer for PDT.

Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections

Targeting secreted aspartic protease 2 (SAP2), a kind of virulence factor, represents a new strategy for antifungal drug discovery. In this report, the first-generation of small molecule SAP2 inhibitors was rationally designed and optimized using a structure-based approach. In particular, inhibitor 23h was highly potent and selective and showed good antifungal potency for the treatment of resistant Candida albicans infections.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).